14 novembre 2020 : à l’occasion de la Journée mondiale du diabète, la société de biotechnologie Adocia a interviewé Delphine Arduini, qui vit avec un diabète de type 1. Avec une attitude extraordinairement positive dans sa vie, cette femme pleine de défis s’explique en 8 épisodes : Portrait de Delphine Arduini, la maladie du diabète,
November 26, 2020, 6pm – 7pmADOCIA Virtual Conference  Dear Madam, Dear Sir, Dear Shareholder,   Thierry de Catheu and Alessandra Fra, co-founders of Biotech Agora, Gérard Soula, Chairman and CEO of ADOCIA and the management team invite you to the ADOCIA videoconference dedicated to you. Meet ADOCIA’s management from the comfort of your home, in
As introduction to the 2020 #BioEurope Partnering Event, #Catherinefeatherston (MC Services Communication Agency) highlights challenges and advantages of virtual events for Biotechs companies, as ADOCIA, Atriva Therapeutics GmbH, Apogenix AG, #heidelbergPharma, Staatz Business Development & Strategy To read the article: https://informaconnect.com/anchors-away-with-virtual-partnering-biotech-buzz-no-longer-tethered-to-kendall-square/
ADOCIA marketing & strategy Director, Jeremy Benattar, will enjoy to meet you at the occasion of BioEurope Virtual event 2020 from October 26th until 29th, 2020! A new occasion to present Adocia strategy and a large pipeline of innovative products as injectable treatments with Insulin (BioChaperone Lispro and BioChaperone Combo), Bi-hormonal treatments as M1Pram then, an emergency treatment:
Adocia’s management will present a review of its activities over the last few months and will discuss the recent clinical results obtained on the M1Pram product. The presentation will be in French, based on an online presentation and will not include a question/answer session. Presentation details: Presenters:  Gérard Soula, President and CEO Olivier Soula, Deputy
This week, Jean-Pierre Vacher received Gérard Soula, Chairman and Adocia CEO, during an interview focused on Adocia’s challenges.
Lyon, France, September 7th, 2020 – 6:00 pm CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that CEO, Gérard Soula, will present a company overview at the H.C. Wainwright 22nd Annual
Adocia to Present Results of the 1st Phase Ib Study of M1Pram (ADO09) at the Annual Congress of the Société Francophone du Diabète (SFD) Adocia will deliver an oral presentation on the 1st Phase Ib Study of M1Pram (ADO09) (pramlintide insulin) at the Annual Congress of the Société Francophone du Diabète. The data were previously
👉 The INPI France patent list filed 2019 ranks Adocia in 4th place among French SMEs thanks to its 11 patents. Among the top 10 French SMEs, 4 are based in the Auvergne-Rhône-Alpes region. This annual ranking classifies companies by region and size. It has become a reference, highlighting the innovation effort made by the
ADA2020 Virtual Expérience is considered as a « smashing success » by organizers. More than 12,500 participants from all over the world were attending for five days scientific advances and groundbreaking research presentations on diabetes. At this occasion, Adocia was exiting to present a Poster presentation of its last results of M1Pram study programme dedicated to type